86,267 Johnson & Johnson $JNJ Shares Sold by Miller Howard Investments Inc. NY

Miller Howard Investments Inc. NY lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 21.4% during the 3rd quarter, Holdings Channel reports. The fund owned 317,257 shares of the company’s stock after selling 86,267 shares during the quarter. Johnson & Johnson comprises 2.3% of Miller Howard Investments Inc. NY’s portfolio, making the stock its 5th largest holding. Miller Howard Investments Inc. NY’s holdings in Johnson & Johnson were worth $83,991,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Westover Capital Advisors LLC raised its position in Johnson & Johnson by 3.8% in the third quarter. Westover Capital Advisors LLC now owns 6,242 shares of the company’s stock valued at $1,653,000 after purchasing an additional 226 shares during the period. Peterson Wealth Services lifted its stake in shares of Johnson & Johnson by 1.9% in the 3rd quarter. Peterson Wealth Services now owns 14,662 shares of the company’s stock valued at $3,882,000 after purchasing an additional 279 shares during the last quarter. Motive Wealth Advisors grew its holdings in shares of Johnson & Johnson by 2.8% during the 3rd quarter. Motive Wealth Advisors now owns 2,137 shares of the company’s stock worth $566,000 after purchasing an additional 59 shares during the period. Leo Wealth LLC purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth $27,789,000. Finally, Apollon Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 6.3% during the 3rd quarter. Apollon Wealth Management LLC now owns 171,511 shares of the company’s stock worth $45,406,000 after purchasing an additional 10,233 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.5%

NYSE:JNJ opened at $275.17 on Friday. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $281.07. The stock’s fifty day moving average is $265.64 and its two-hundred day moving average is $246.62. The stock has a market capitalization of $662.42 billion, a price-to-earnings ratio of 25.45, a price-to-earnings-growth ratio of 2.68 and a beta of 0.21. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 64,515 shares of company stock valued at $17,271,766 in the last three months. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on JNJ. Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a report on Thursday, October 15th. Evercore set a $300.00 target price on shares of Johnson & Johnson in a research note on Tuesday, October 20th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research report on Tuesday, September 29th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research note on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde gains traction in plaque psoriasis. Independent physician research indicates that Johnson & Johnson’s oral therapy is being adopted quickly in U.S. dermatology practices and gaining share among oral advanced treatments. Earlier use could expand Icotyde’s revenue opportunity and delay treatment with more expensive biologics. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: Newer products are helping offset Stelara’s decline. J&J’s stock has gained substantially over the past year as newer medicines compensate for pressure on Stelara, while the company works toward resolving ovarian talc claims. Johnson & Johnson Is Up 42% in a Year: Take Profits, or Buy More?
• Positive Sentiment: Medical-device evidence supports Impella. J&J presented a record 26 abstracts at TCT 2026, adding to more than two decades of data on the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may reinforce adoption of the cardiovascular device franchise. Johnson & Johnson Record 26 Abstracts at TCT 2026
• Positive Sentiment: Recent operating results remain supportive. J&J exceeded quarterly earnings expectations, with revenue rising year over year, and reaffirmed fiscal 2026 earnings guidance. Its diversified drug and device portfolio has also benefited from continued progress in arthritis treatments and regulatory expansion. Johnson & Johnson Strong Q3 Growth, But 2027 Could Test Its Earnings
• Neutral Sentiment: Analyst sentiment is generally favorable, but broker ratings are already reflected in the stock’s strong run and do not by themselves provide a new earnings catalyst. Johnson & Johnson Is Considered a Good Investment by Brokers
• Negative Sentiment: Investors face longer-term earnings and legal risks. Stelara’s erosion, potential 2027 earnings pressure and J&J’s premium valuation could limit further upside. Separately, Pomerantz announced an investigation into potential investor claims related to the company; the announcement is not a finding of wrongdoing but could add headline and litigation risk. Pomerantz Investor Alert Regarding Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.